Difference between revisions of "Aminoglutethimide (Cytadren)"
m (Text replacement - "http://chemocare.com/chemotherapy" to "https://chemocare.com/chemotherapy") |
m |
||
| Line 6: | Line 6: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/cytadren-aminoglutethimide-342878 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/cytadren-aminoglutethimide-342878 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| − | ==Diseases for which it | + | ==Diseases for which it was used== |
*[[Breast cancer]] | *[[Breast cancer]] | ||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
| Line 28: | Line 27: | ||
[[Category:Steroid synthesis inhibitors]] | [[Category:Steroid synthesis inhibitors]] | ||
[[Category:Aromatase inhibitors]] | [[Category:Aromatase inhibitors]] | ||
| − | [[Category:Breast cancer medications]] | + | [[Category:Breast cancer medications (historic)]] |
| − | + | ||
[[Category:FDA approved in 1980]] | [[Category:FDA approved in 1980]] | ||
Revision as of 01:54, 26 April 2022
General information
Class/mechanism: Inhibitor of adrenalcortical steroid synthesis, blocks conversion of cholesterol to pregnenolone and subsequent synthesis of adrenal steroids, has aromatase inhibitor activity.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it was used
Patient drug information
History of changes in FDA indication
This medication does not have a specific cancer indication; it is indicated for Cushing Syndrome.
- 10/29/1980: Initial approval
Also known as
- Brand names: Aminoblastin, Cytadren, Elipten, Orimentin, Orimeten, Orimetene, Rodazol